The use of CDK inhibitors in oncology: A pharmaceutical perspective

Cell Cycle

Volumn 3, Issue 6, 2004, Pages 740-744

  Fischer, Peter M ^a,b  

^a CYCLACEL LTD   (United Kingdom)

^b Cydacel Limited   (United Kingdom)

Author keywords

ATP antagonist; Cancer; CDK; Cell cycle; Inhibitor; Kinase; Transcription regulation

Indexed keywords

(5 OXO 2,3,5,9B TETRAHYDRO 1H PYRROLO[2,1 A]ISOINDOL 9 YL)UREA; 2,4 BIS(2 AMINOPYRIMIDIN 4 YL)PHENOL; 7 HYDROXYSTAUROSPORINE; BMI 1026; CARBOPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; FLAVOPIRIDOL; IRINOTECAN; ISOENZYME; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; ROSCOVITINE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE; CELL TRANSFORMATION; DNA TRANSCRIPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INDICATION; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; ONCOLOGY; PHARMACOPHORE; PROTEIN FUNCTION; REVIEW;

EID: 13244255220     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.6.937     Document Type: Review

References (76)

1. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
2. 1/S transition. Curr Genomics 2002; 3:245-63.
3. Hinds PW. Cdk2 dethroned as master of S phase entry. Cancer Cell 2003; 3:305-7.
4. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Disc 2003; 2:296-313.
5. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31.
6. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13:1775-85.
7. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell 2003; 114:431-43.
8. Blagosklonny MV. Do cells need CDK2 and ...Bcr-Abl? Cell Death Differ 2004; 11:249-51.
9. 1 cyclin-dependent kinase activity. Genes Dev 1995; 9:2873-87.
10. Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003; 63:1020-4.
11. Chen Y-NP, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999; 96:4325-9.
12. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11:961-71.
13. 1-to-S phase transition. Mol Cell Biol 1995; 15:2612-24.
14. 1-to-S transition in mammalian cells. Oncogene 1993; 8:1593-602.
15. 2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001; 21:2755-66.
16. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262:2050-4.
17. Li K, Lin S-Y, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003; 63:3593-7.
18. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45.
19. Grim JE, Clurman BE. Cycling without CDK2? Trends Cell Biol 2003; 13:396-9.
20. Mendez J. Cell Proliferation without Cyclin E-CDK2. Cell 2003; 114:3 98-9.
21. Guadagno TM, Newport JW. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 1996; 84:73-82.
22. Matsumoto Y, Hayashi K, Nishida E. Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 1999; 9:429-32.
23. Fischer PM, Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Exp Opin Investig Drugs 2003; 12:955-70.
24. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003; 22:6609-20.
25. Kong N, Fotouhi N, Wovkulich PM, Roberts J. Cell cycle inhibitors for the treatment of cancer. Drugs of the Future 2003; 28:881-96.
26. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23:417-25.
27. Grant S, Roberts John D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat 2003; 6:15-26.
28. Hotte SJ, Oza A, Winquist EW, Jasas K, Degendorfer P, Dancey JE, et al. Phase II study of topotecan (T) in combination with the novel kinase inhibitor UCN-01 in patients with advanced cancer. Clin Cancer Res 2003; 9:C80.
29. Hakimian RR, Edelman MJ, Bauer K, Wu S, Smith R, Dancey J, et al. Phase I and pharmacokinetic (PK) study of the cyclin dependent kinase (CDK) inhibitor UCN-01 and carboplatin in solid tumors. Proc Am Soc Clin Oncol 2003; 22:149.
30. Shah MA, Kortmansky J, Gonen M, Drobjnak M, Kemeny N, Saltz LB, et al. Mature results of a phase I study of irinotecan (CPT) and flavopiridol (F): A clinically and biologically active regimen. Proc Am Soc Clin Oncol 2003; 22:262.
31. Kasimis B, Rocha-Lima C, Cogswell J, Mahany JJ, Rodriguez L, Gries J-M. Phase I study evaluating 1-hour flavopiridol (HMR1275) in combination with docetaxel (D) in previously treated nonsmall cell lung cancer (NSCLC) patients (pts)(HMR1275B/1008). Proc Am Soc Clin Oncol 2003; 22:669.
32. Wang S, McClue SJ, Ferguson JR, Hull JD, Stokes S, Parsons S, et al. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry 2001; 12:2891-4.
33. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002; 190:160-9.
34. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001; 60:785-9.
35. Chao S-H, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276:31793-9.
36. Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 2002; 50:779-92.
37. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102:463-8.
38. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 2003; 106:486-95.
39. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001; 20:3206-16.
40. Gojo I, Zhang B, Fenton RG. The Cyclin-dependent kinase inhibitor flavopiridol Induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8:3527-38.
41. Alvi AJ, Gianella-Botradori A, Lane DP, Austen B, Moss P, Stankovic T. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-cell chronic lymphocytic leukaemia by down-regulation of genes involved in transcription regulation and repair. Blood 2003; 102:1587.
42. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91:2482-90.
43. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, et al. Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial. Clin Cancer Res 2003; 9:307-15.
44. Mohapatra S, Chu B, Wei S, Djeu J, Epling-Burnette PK, Loughran T, et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 2003; 63:8523-30.
45. Pepper C, Thomas A, Hoy T, Tighe J, Culligan D, Fegan C, et al. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle 2003; 2:53-8.
46. Semenov I, Akyuz C, Roginskaya V, Chauhan D, Corey SJ. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leukemia Res 2002; 26:271-80.
47. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63:93-9.
48. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2FI and repression of Mcl-I. Mol Cancer Ther 2003; 2:73-81.
49. Jiang J, Matranga CB, Cai D, Latham Jr VM, Zhang X, Lowell AM, et al. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 2003; 63:7410-22.
50. Misra RN, Xiao H-Y, Barbosa SA, Kim KS, Lu S, Han W-C, et al. SAR and solid-state structure of BMS-387032: A potent and selective CDK2 inhibitor with anti-tumor activity. Proc Amer Assoc Cancer Res 2003; 44:3976.
51. Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao H-Y, et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002; 45:3905-27.
52. Shapiro G, Lewis N, Bai S, Van Leeuwen B, Mauro D, Youssoufian H, et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22:199.
53. McCormick J, Gadgeel SM, Helmke W, Chaplen R, Van Leeuwen B, Mauro D, et al. Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Proc Am Soc Clin Oncol 2003; 22:208.
54. Jones SF, Burris HA, Kies M, Willcutt N, Degen P, Bai S, et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22:199.
55. Wong TW, Kimball D, Misra RN, Kim K, Lee F, Kellar K, et al. BMS-387032, A potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), induces cell cycle arrest and apoptosis in human tumor cells. Proc Amer Assoc Cancer Res 2003; 44:3125.
56. Walton MI. Studies on the molecular pharmacology of the CDK2 inhibitor BMS-387032 in human tumour cell lines. Clin Cancer Res 2003; 9:C89.
57. Wong TW, Wang C, Lee F, Shaw P, Letrent S, Mauro D, et al. Identification of a biomarker of CDK2 inhibition with BMS-387032. Clin Cancer Res 2003; 9:C84.
58. Lee FYF, Camuso A, Clark J, Fager K, Inigo I, Kan D, et al. BMS-387032, A selective inhibitor of cyclin-dependent kinase 2 with potent anti-tumor activity in vivo. Proc Amer Assoc Cancer Res 2003; 44:958.
59. Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr Med Chem Anti-Cancer Agents 2003; 3:1-14.
60. Seong Y-S, Min C, Li L, Yang JY, Kim S-Y, Cao X, et al. Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026. Cancer Res 2003; 63:7384-91.
61. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem J 2003; 371:199-204.
62. Knockaert M, Gray N, Damiens E, Chang Y-T, Grellier P, Grant K, et a. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem Biol 2000; 7:411-22.
63. Fischer PM. CDK versus GSK-3 inhibition: A purple haze no longer? Chem Biol 2003; 10:1144-6.
64. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR analysis, X-Ray crystallography, and biological activity. J Med Chem 2004; 47:1662-75.
65. Kim KS, Sack JS, Tokarski JS, Qian L, Chao ST, Leith L, et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects. J Med Chem 2000; 43:4126-34.
66. Fischer PM. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Disc Dev 2001; 4:623-34.
67. Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N, Fukasawa K, et al. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem 2001; 44:4628-40.
68. Harvey PJ, Keller PR, Toogood PL, VanderWel S, McNamera D, Fry DW. Biological response to Cdk inhibitors as a determinant of Cdk4 vs Cdk2 selectivity. Proc Amer Assoc Cancer Res 2003; 44:3120.
69. Hiddemann W, Dreyling M. Mantle cell lymphoma: Therapeutic strategies are different from CLL. Curr Treat Options Oncol 2003; 4:219-26.
70. Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leukemia Lymphoma 2002; 43:793-7.
71. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002; 277:33922-9.
72. Shima D, Yugami M, Tatsuno M, Wada T, Yamaguchi Y, Handa H. Mechanism of H-8 inhibition of Cyclin-dependent kinase 9: Study using inhibitor-immobilized matrices. Genes To Cells 2003; 8:215-23.
73. Pratt DJ, Boyle T, Cheng Y, Curtin N, Endicott J, Holton S, et al. Inhibition of cyclin dependent kinases: Aspects of selectivity. Proc Amer Assoc Cancer Res 2003; 44:3972.
74. Canduri F, da Silveira NJF, Camera Jr JC, de Azevedo Jr WF. Structural bionformatics study of cyclin-dependent kinases complexed with inhibitors. Ecletica Quimica 2003; 28:45-53.
75. McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, et al. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol 2004; in press.
76. de la Fuente C, Maddukuri A, Kehn K, Baylor SY, Deng L, Pumfery A, et al. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res 2003; 1:131-52.